The known unknowns of the Hsp90 chaperone

Laura-Marie Silbermann,Benjamin Vermeer,Sonja Schmid,Katarzyna,Tych
2023-08-31
Abstract:Molecular chaperones are vital proteins that maintain protein homeostasis by assisting in protein folding, activation, degradation, and stress protection. Among them, heat-shock protein 90 (Hsp90) stands out as an essential proteostasis hub in eukaryotes, chaperoning hundreds of "clients" (substrates). After decades of research, several "known unknowns" about the molecular function of Hsp90 remain unanswered, hampering rational drug design for the treatment of cancers, neurodegenerative and other diseases. We highlight three fundamental open questions, reviewing the current state of the field for each, and discuss new opportunities, including single-molecule technologies, to answer the known unknowns of the Hsp90 chaperone.
Biomolecules,Biological Physics
What problem does this paper attempt to address?
The paper attempts to address issues primarily focused on the functional mechanisms of the molecular chaperone protein Hsp90. Specifically, although Hsp90 plays a crucial role in protein folding, activation, degradation, and stress protection, and has been extensively studied for decades, there remain some "known unknowns" regarding its molecular functions. These unresolved mysteries include: 1. **What is the role of Hsp90's ATPase activity?** - Although Hsp90 is an important ATPase, the specific role of its ATP hydrolysis remains unclear. ATP hydrolysis is well-defined for many standard ATPases, but for Hsp90, its function has not been fully elucidated. 2. **How does Hsp90 handle its wide range of client proteins?** - Hsp90 interacts with a variety of different types of client proteins, but the specific molecular mechanisms are not well understood. Typically, only the final outcomes (such as functional client proteins) can be observed, while the intermediate processes remain unknown. 3. **What is the interaction sequence of the Hsp90 system?** - The interaction sequence between Hsp90 and other molecular chaperones and client proteins, as well as which steps are reversible and which are unidirectional, is currently unclear. Additionally, it is not fully understood which steps are rapid and which are rate-limiting. These issues hinder rational drug design for the treatment of diseases such as cancer and neurodegenerative disorders. The paper highlights these problems and discusses new technological approaches, particularly single-molecule techniques, to address these known unknowns. Through these studies, it is hoped that a better molecular-level understanding of Hsp90's functional mechanisms can be achieved, thereby advancing the relevant fields.